Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dickson

Showing results (571-580 of 623) with videos related to

Pageof 63
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Sarcoma|June 16, 2015
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue SarcomaMark A Dickson, David R D'Adamo, Mary L Keohan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
The Oncologist|June 20, 2019
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal TumorEvan Rosenbaum, Ciara Kelly, Sandra P D'Angelo, et al.
ESMO Open|March 21, 2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcomaO O Babatunde, K Seier, G Schwartz, et al.
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Disease-A-Month : DM|September 22, 2023
Health equity in pediatrics: Current concepts for the care of children in the 21st century (Dis Mon)Cheryl A Dickson, Berrin Ergun-Longmire, Donald E Greydanus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2024
Phase II Trial of <i>nab-</i>Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety UpdateAndrew J Wagner, Vinod Ravi, Richard F Riedel, et al.
Cancer Medicine|June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II TrialsAdel Shahnam, Kristen DiConza, Simran Jasnani, et al.
Pageof 63

Showing results (571-580 of 623) with videos related to

Sort By:
Pageof 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Sarcoma|June 16, 2015
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue SarcomaMark A Dickson, David R D'Adamo, Mary L Keohan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
The Oncologist|June 20, 2019
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal TumorEvan Rosenbaum, Ciara Kelly, Sandra P D'Angelo, et al.
ESMO Open|March 21, 2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcomaO O Babatunde, K Seier, G Schwartz, et al.
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Disease-A-Month : DM|September 22, 2023
Health equity in pediatrics: Current concepts for the care of children in the 21st century (Dis Mon)Cheryl A Dickson, Berrin Ergun-Longmire, Donald E Greydanus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2024
Phase II Trial of <i>nab-</i>Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety UpdateAndrew J Wagner, Vinod Ravi, Richard F Riedel, et al.
Cancer Medicine|June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II TrialsAdel Shahnam, Kristen DiConza, Simran Jasnani, et al.
Pageof 63